Rosa Rademakers Wins Breakthrough Prize for Dementia and ALS Research

Belgian neuroscientist Rosa Rademakers has been awarded the 2026 Breakthrough Prize in Life Sciences, often referred to as the “Oscars of science,” for her pioneering research into the genetic mechanisms underlying frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The $3 million prize, announced at a ceremony in Los Angeles attended by Hollywood celebrities and scientific leaders, recognizes her work identifying key genetic mutations that drive these devastating neurodegenerative diseases.

Rademakers, a professor at the VIB-UAntwerp Center for Molecular Neurology and the Born-Bunge Foundation, led an international team that discovered how expansions in the C9orf72 gene — a repetitive DNA sequence — cause both FTD and ALS in a significant proportion of familial cases. Her research, published over the past decade in leading journals including Neuron and Nature Genetics, established that this genetic anomaly leads to toxic RNA repeats and abnormal protein production, ultimately killing neurons in the brain and spinal cord.

Linking Two Devastating Diseases Through Genetics

Frontotemporal dementia, the second most common form of early-onset dementia after Alzheimer’s disease, primarily affects behavior, personality, and language. ALS, also known as Lou Gehrig’s disease, progressively destroys motor neurons, leading to muscle weakness, paralysis, and respiratory failure. Though clinically distinct, both conditions share pathological and genetic overlaps, particularly in cases involving the C9orf72 mutation.

From Laboratory Discovery to Global Recognition

Rademakers’ breakthrough came through large-scale genetic screening of patient families across Europe and North America. By comparing genomes of individuals with inherited FTD or ALS to healthy controls, her team identified the C9orf72 repeat expansion as the most common genetic cause of both diseases, accounting for up to 40% of familial cases in some populations.

Implications for Diagnosis and Future Therapies

The discovery has already transformed clinical practice. Genetic testing for C9orf72 expansions is now standard in neurology clinics when evaluating patients with suspected familial FTD or ALS, enabling earlier diagnosis and informed family counseling. More importantly, the findings have opened new avenues for therapeutic development, including antisense oligonucleotides and gene-editing strategies aimed at reducing the toxic RNA or protein products of the mutation.

A Personal Journey Behind the Science

I never told my daughters about my work for years — not because I wanted to hide it, but because I didn’t want them to worry. Science is a slow process, and hope needs to be grounded in evidence.

— Rosa Rademakers, Breakthrough Prize ceremony, April 2026

Continued Research and Global Collaboration

Rademakers emphasizes that while the C9orf72 discovery was pivotal, much remains unknown about why some carriers develop FTD, others ALS, and some both — or neither. Her current research focuses on modifier genes, environmental influences, and neuroinflammatory responses that may influence disease onset and progression. She continues to collaborate with consortia such as the ALS Association’s Precision Medicine Program and the European Joint Programme on Neurodegenerative Disease Research (JPND).

Context: The Burden of Neurodegenerative Disease

According to the World Health Organization, over 55 million people live with dementia globally, with nearly 10 million new cases each year. ALS affects approximately 2 to 3 people per 100,000 worldwide, with no known cure. In Belgium, where Rademakers conducts her research, neurodegenerative diseases are a growing public health concern due to an aging population.

Looking Ahead

The Breakthrough Prize, founded in 2012 by Sergey Brin, Priscilla Chan, Mark Zuckerberg, Yuri Milner, and Anne Wojcicki, aims to celebrate transformative advances in fundamental physics, life sciences, and mathematics. Rademakers is the second Belgian scientist to receive the award in its history, following microbiologist Peter Piot’s recognition in 2018 for HIV/AIDS research.

As she accepts the honor, Rademakers remains focused on the next steps: translating genetic insights into effective treatments. “The prize is a tribute to decades of teamwork,” she said in an interview with De Standaard. “But the real award will be when You can offer a patient a therapy that changes the course of their disease.”